0001193125-11-299291.txt : 20111107
0001193125-11-299291.hdr.sgml : 20111107
20111107131847
ACCESSION NUMBER: 0001193125-11-299291
CONFORMED SUBMISSION TYPE: 13F-HR
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20110930
FILED AS OF DATE: 20111107
DATE AS OF CHANGE: 20111107
EFFECTIVENESS DATE: 20111107
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: BB BIOTECH AG
CENTRAL INDEX KEY: 0000924223
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 13F-HR
SEC ACT: 1934 Act
SEC FILE NUMBER: 028-06964
FILM NUMBER: 111183799
BUSINESS ADDRESS:
STREET 1: VODERGASSE 3
STREET 2: SWITZERLAND
CITY: SCHAFFHAUSEN
STATE: V8
ZIP: CH-8300
BUSINESS PHONE: 411724 59 59
MAIL ADDRESS:
STREET 1: VODERGASSE 3
STREET 2: SWITZERLAND
CITY: SCHAFFHAUSEN
STATE: V8
ZIP: CH-8300
13F-HR
1
d254002d13fhr.txt
FORM 13 HOLDING REPORT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 13F
Form 13F COVER PAGE
Report for Calendar Year or Quarter Ended: September 30, 2011
Check here if Amendment [ ]; Amendment Number:
This Amendment (Check only one.): [ ] is a restatement.
[ ] adds new holdings entries.
Institutional Investment Manager Filing this Report:
Name: BB Biotech AG
Address: Vordergasse 3
Schaffhausen Switzerland CH-8200
Form 13F File Number: 28-6964
The institutional investment manager filing this report and the person by whom
it is signed hereby represent that the person signing the report is authorized
to submit it, that all information contained herein is true, correct and
complete, and that it is understood that all required items, statements,
schedules, lists, and tables are considered integral parts of this form.
Person Signing this Report on Behalf of Reporting Manager:
Name: Pascal Schmucki
Title: SIGNING AUTHORITY
Phone: 41 (44) 267 67 00
Signature, Place, and Date of
Signing: /s/ Pascal Schmucki
-------------------------------------------
Schaffhausen, Switzerland, November 4, 2011
Report Type (Check only one.):
[X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager
are reported in this report.)
[ ] 13F NOTICE. (Check here if no holdings reported are in this report, and
all holdings are reported by other reporting manager(s).)
[ ] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this
reporting manager are reported in this report and a portion are reported by
other reporting manager(s).)
Form 13F SUMMARY PAGE
Report Summary:
Number of Other Included Managers: 3
Form 13F Information Table Entry Total: 20
Form 13F Information Table Value Total: $ 850,661
-----------
(thousands)
List of Other Included Managers:
Provide a numbered list of the name(s) and Form 13F file number(s) of all
institutional investment managers with respect to which this report is filed,
other than the manager filing this report.
No. Form 13F File Number Name
--- -------------------- -------------------
1 28-11193 Biotech Focus N.V.
2 28-11191 Biotech Invest N.V.
3 28-11189 Biotech Target N.V.
2
BB BIOTECH AG
FORM 13F INFORMATION TABLE
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
---------------------- -------- --------- -------- ------------------ ---------- -------- ---------------------
VOTING AUTHORITY
TITLE VALUE SHS OR SH/ PUT/ INVESTMENT OTHER ---------------------
NAME OF ISSUER OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE
-------------- -------- --------- -------- --------- --- ---- ---------- -------- --------- ------ ----
Achillion
Pharmaceuticals Inc COM 00448Q201 9,515 2,015,840 SH DEFINED 3 2,015,840 NONE NONE
Alexion
Pharmaceuticals Inc COM 015351109 28,827 450,000 SH DEFINED 2 450,000 NONE NONE
Amgen Inc COM 031162100 16,488 300,000 SH DEFINED 1 300,000 NONE NONE
Amylin Pharmaceuticals
Inc COM 032346108 22,043 2,388,139 SH DEFINED 2 2,388,139 NONE NONE
Biomarin
Pharmaceutical Inc COM 09061G101 31,091 975,545 SH DEFINED 2 975,545 NONE NONE
Celgene Corp COM 151020104 191,921 3,100,000 SH DEFINED 2 3,100,000 NONE NONE
Dendreon Corp COM 24823Q107 13,721 1,524,500 SH DEFINED 2 1,524,500 NONE NONE
Endocyte Inc COM 29269A102 3,260 307,510 SH DEFINED 3 307,510 NONE NONE
Gilead Sciences Inc COM 375558103 100,880 2,600,000 SH DEFINED 1 2,600,000 NONE NONE
Halozyme Therapeutics
Inc COM 40637H109 30,700 5,000,000 SH DEFINED 3 5,000,000 NONE NONE
Human Genome Sciences
Inc COM 444903108 19,937 1,571,056 SH DEFINED 2 1,571,056 NONE NONE
Idenix Pharmaceuticals
Inc COM 45166R204 12,387 2,482,308 SH DEFINED 3 2,482,308 NONE NONE
Immunogen Inc COM 45253H101 43,840 4,000,000 SH DEFINED 3 4,000,000 NONE NONE
Incyte Corp COM 45337C102 65,170 4,665,000 SH DEFINED 3 4,665,000 NONE NONE
Isis Pharmaceuticals COM 464330109 37,968 5,600,000 SH DEFINED 3 5,600,000 NONE NONE
Micromet Inc COM 59509C105 32,071 6,681,397 SH DEFINED 3 6,681,397 NONE NONE
Optimer
Pharmaceuticals Inc COM 68401H104 19,967 1,442,700 SH DEFINED 3 1,442,700 NONE NONE
Pharmasset Inc COM 71715N106 32,754 397,650 SH DEFINED 3 397,650 NONE NONE
Theravance Inc COM 88338T104 16,983 843,244 SH DEFINED 3 843,244 NONE NONE
Vertex
Pharmaceuticals Inc COM 92532F100 121,138 2,724,653 SH DEFINED 3 2,724,653 NONE NONE
3